New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 13, 2013
16:16 EDTTRGTTargacept reports Q4 EPS (47c), consensus (31c)
Reports Q4 revenue $590,000, consensus $830,000.
News For TRGT From The Last 14 Days
Check below for free stories on TRGT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 15, 2014
10:28 EDTTRGTHigh option volume stocks
High option volume stocks: TRGT ALB UUP ADHD ROC WWW CTRL KERX IMGN NI
July 14, 2014
15:37 EDTTRGTTargacept resumes trading, down 12% following study failure
Subscribe for More Information
15:13 EDTTRGTTargacept to resume trading at 3:35 pm ET
Subscribe for More Information
15:08 EDTTRGTTargacept confirms Alzheimer’s trial does not show superiority of TC-1734
Targacept announced top-line results from a Phase 2b monotherapy clinical trial of TC-1734 as a treatment for mild to moderate Alzheimer’s disease. In the trial, TC-1734 did not meet the objective of showing superiority to donepezil, the marketed medication most often prescribed for Alzheimer’s disease, after 52 weeks of treatment. The trial did not include a placebo arm and was not designed to determine whether TC-1734 is equivalent to donepezil. The co-primary endpoints for the study were measures of cognitive function and global function. Consistent with previous clinical results, TC-1734 exhibited a benign safety and tolerability profile. Targacept President and CEO Dr. Stephen A. Hill said, “We are disappointed for Alzheimer’s disease patients and their families. We designed a rigorous study to provide a definitive answer on whether TC-1734 could be a better treatment option than the current standard of care in what has been a very difficult disease area for the development of novel therapeutics. Based on these results, we do not intend to invest in further development of TC-1734.” Analyses of the full dataset from the trial are ongoing and Targacept plans to present and publish more detailed results over the coming months, the company said.
15:08 EDTTRGTTargacept does not intend to invest in further TC-1734 development
Subscribe for More Information
15:08 EDTTRGTTargacept confirms Alzheimer’s trial does not show superiority of TC-1734
Subscribe for More Information
14:37 EDTTRGTTargacept Alzheimer's study said to fail, TheStreet's Feuerstein says
Subscribe for More Information
14:36 EDTTRGTTargacept halted for trading following reports of study failure
14:32 EDTTRGTTargacept halted for volatility after dropping 16% to $3.71
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use